SEC Form 4 · accession 0001019056-16-001455

Aptevo Therapeutics Inc. · APVO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Aug 3, 2016

Accepted (ET)

Aug 5, 2016 · 7:43 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001671584

Table I — non-derivative securities

Security	Date	Code	Shares	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	holding	—	—	—	824,536	D
Common Stock^F1,F2	holding	—	—	—	2,172,125	I	By Intervac, L.L.C.
Common Stock^F1,F3	holding	—	—	—	762,077	I	By Biovac, L.L.C.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F4	$2.94	Aug 3, 2016	A	18,750	A	—	Aug 3, 2026	Common Stock	18,750	18,750	D

F1Shares received in a pro rata distribution by Emergent BioSolutions Inc. ("Emergent") as a result of the spin-off of the Issuer from Emergent, effective on August 1, 2016.
F2Mr. El-Hibri, together with his wife, holds a 37.7% equity interest in Intervac, L.L.C. which in turn beneficially owns an aggregate of 2,172,125 shares of the Issuer's common stock. Mr. El-Hibri expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by Intervac, L.L.C., except to the extent of his pecuniary interest therein.
F3Mr. El-Hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 762,077 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Biovac, L.L.C., except to the extent of his pecuniary interest therein.
F4The stock options were granted on August 3, 2016 and vest in three equal installments on August 3, 2017, August 3, 2018 and August 3, 2019.